Austin G Stack1, David Han2, Ronald Goldwater3, Susanne Johansson4, Nalina Dronamraju5, Jan Oscarsson4, Eva Johnsson4, Joanna Parkinson4, Fredrik Erlandsson4. 1. University Hospital Limerick, School of Medicine and Health Research Institute (HRI), University of Limerick, Limerick, Ireland. 2. Parexel International, Glendale, California, USA. 3. Parexel International, Baltimore, Maryland, USA. 4. AstraZeneca BioPharmaceuticals Research and Development, Gothenburg, Sweden. 5. AstraZeneca BioPharmaceuticals Research and Development, Gaithersburg, Maryland, USA.
Abstract
CONTEXT: Combining a sodium-glucose cotransporter 2 inhibitor with a xanthine oxidase inhibitor (XOI) and a urate transporter 1 (URAT1) inhibitor may enhance serum uric acid (sUA) lowering. However, concerns exist regarding high urinary UA (uUA) excretion rates and subsequent crystallization in renal tubules. OBJECTIVE: To assess whether dapagliflozin added to verinurad, a selective URAT1 inhibitor, and febuxostat, an XOI, increases uUA excretion. DESIGN: Randomized, placebo-controlled, 2-way crossover study (NCT03316131). PATIENTS: Adults with asymptomatic hyperuricemia. INTERVENTIONS:Subjects (N = 36) were randomized to oral once-daily 9 mg verinurad plus 80 mg febuxostat plus 10 mg dapagliflozin for 7 days and 7 days of oral once-daily 9 mg verinurad plus 80 mg febuxostat plusplacebo with an intervening 7- to 21-day washout period. MAIN OUTCOME MEASURE: Difference in peak uUA excretion between groups from baseline to day 7. Secondary outcomes included changes in sUA levels and 24-huUA excretion. RESULTS: Both regimens lowered mean peak uUA excretion (least squares mean changes from baseline: -12.9 mg/h [95% confidence interval (CI): -21.0 to -4.7], dapagliflozin; -13.2 mg/h [95% CI -21.3 to -5.0], placebo). sUA concentrations were lower with dapagliflozin (mean treatment difference -62.3 µmol/L [95% CI -82.8 to -41.8]). Dapagliflozin did not impact verinurad pharmacokinetics, its main metabolites, or febuxostat or fasting plasma glucose levels vs verinurad plus febuxostat. There were no clinically relevant changes in safety parameters. CONCLUSIONS:Dapagliflozin further reduced sUA without influencing uUA excretion, suggesting that its combination with verinurad and febuxostat at the doses tested does not adversely affect kidney function. CLINICAL TRIAL REGISTRATION NUMBER: NCT03316131.
RCT Entities:
CONTEXT: Combining a sodium-glucose cotransporter 2 inhibitor with a xanthine oxidase inhibitor (XOI) and a urate transporter 1 (URAT1) inhibitor may enhance serum uric acid (sUA) lowering. However, concerns exist regarding high urinary UA (uUA) excretion rates and subsequent crystallization in renal tubules. OBJECTIVE: To assess whether dapagliflozin added to verinurad, a selective URAT1 inhibitor, and febuxostat, an XOI, increases uUA excretion. DESIGN: Randomized, placebo-controlled, 2-way crossover study (NCT03316131). PATIENTS: Adults with asymptomatic hyperuricemia. INTERVENTIONS: Subjects (N = 36) were randomized to oral once-daily 9 mg verinurad plus 80 mg febuxostat plus 10 mg dapagliflozin for 7 days and 7 days of oral once-daily 9 mg verinurad plus 80 mg febuxostat plus placebo with an intervening 7- to 21-day washout period. MAIN OUTCOME MEASURE: Difference in peak uUA excretion between groups from baseline to day 7. Secondary outcomes included changes in sUA levels and 24-h uUA excretion. RESULTS: Both regimens lowered mean peak uUA excretion (least squares mean changes from baseline: -12.9 mg/h [95% confidence interval (CI): -21.0 to -4.7], dapagliflozin; -13.2 mg/h [95% CI -21.3 to -5.0], placebo). sUA concentrations were lower with dapagliflozin (mean treatment difference -62.3 µmol/L [95% CI -82.8 to -41.8]). Dapagliflozin did not impact verinurad pharmacokinetics, its main metabolites, or febuxostat or fasting plasma glucose levels vs verinurad plus febuxostat. There were no clinically relevant changes in safety parameters. CONCLUSIONS:Dapagliflozin further reduced sUA without influencing uUA excretion, suggesting that its combination with verinurad and febuxostat at the doses tested does not adversely affect kidney function. CLINICAL TRIAL REGISTRATION NUMBER: NCT03316131.
Authors: Alicia Swee Yan Yip; Shariel Leong; Yao Hao Teo; Yao Neng Teo; Nicholas L X Syn; Ray Meng See; Caitlin Fern Wee; Elliot Yeung Chong; Chi-Hang Lee; Mark Y Chan; Tiong-Cheng Yeo; Raymond C C Wong; Ping Chai; Ching-Hui Sia Journal: Ther Adv Chronic Dis Date: 2022-03-23 Impact factor: 5.091
Authors: Hiddo J L Heerspink; Austin G Stack; Robert Terkeltaub; Tom A Greene; Lesley A Inker; Magnus Bjursell; Shira Perl; Tord Rikte; Fredrik Erlandsson; Vlado Perkovic Journal: Nephrol Dial Transplant Date: 2022-07-26 Impact factor: 7.186
Authors: Elmar Zügner; Hsiu-Chiung Yang; Petra Kotzbeck; Beate Boulgaropoulos; Harald Sourij; Sepideh Hagvall; Charles S Elmore; Russell Esterline; Sven Moosmang; Jan Oscarsson; Thomas R Pieber; Xiao-Rong Peng; Christoph Magnes Journal: Int J Mol Sci Date: 2022-07-19 Impact factor: 6.208